Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 53 results for ng191

  1. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  2. COVID-19 prescribing briefing: corticosteroids

    Dexamethasone and hydrocortisone are both corticosteroids; they have a role in treating COVID-19 in certain people.

  3. What are the views, preferences and experiences of people with COVID-19-associated pulmonary aspergillosis (CAPA), and their families or carers, on:• available tests for diagnosing CAPA• available treatments for CAPA?

    Recommendation ID NG191/13 Question What are the views, preferences and experiences of people with COVID-19-associated pulmonary...

  4. Does a multidisciplinary team agreed approach to weaning from continuous positive airway pressure improve weaning times and result in stopping continuous positive airway pressure for people with COVID-19 and acute respiratory failure?

    Recommendation ID NG191/6 Question Does a multidisciplinary team agreed approach to weaning from continuous positive airway pressure...

  5. What is the clinical and cost effectiveness of budesonide for treating COVID-19 in the community in adults, young people and children?

    Recommendation ID NG191/9 Question What is the clinical and cost effectiveness of budesonide for treating COVID-19 in the community in

  6. What is the effectiveness, cost effectiveness and safety of using a combination of casirivimab and imdevimab at doses other than 8 g for treating COVID-19?

    Recommendation ID NG191/7 Question What is the effectiveness, cost effectiveness and safety of using a combination of casirivimab and...

  7. What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs) compared with a standard prophylactic dose for venous thromboembolism (VTE) prophylaxis in young people under 18 years with COVID-19?

    Recommendation ID NG191/3 Question What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs)

  8. Does early review and referral to specialist palliative care services improve outcomes for adults with COVID-19 thought to be approaching the end of their life?

    Recommendation ID NG191/4 Question Does early review and referral to specialist palliative care services improve outcomes for adults with

  9. What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis for people who have been discharged after treatment for COVID-19?

    Recommendation ID NG191/2 Question What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE)...

  10. What risk factors in people who are critically ill and have, or have had, COVID-19 as part of their acute illness are associated with developing COVID-19-associated pulmonary aspergillosis (CAPA)?

    Recommendation ID NG191/10 Question What risk factors in people who are critically ill and have, or have had, COVID-19 as part of their

  11. What is the effectiveness and safety of neutralising monoclonal antibodies against different SARS-CoV-2 variants?

    Recommendation ID NG191/15 Question What is the effectiveness and safety of neutralising monoclonal antibodies against different...

  12. In people with suspected COVID-19-associated pulmonary aspergillosis (CAPA), what are the most accurate tests for diagnosing the infection and when should they be done?

    Recommendation ID NG191/12 Question In people with suspected COVID-19-associated pulmonary aspergillosis (CAPA), what are the most...

  13. What are the possible outcomes for people who are critically ill and have COVID-19-associated pulmonary aspergillosis (CAPA)?

    Recommendation ID NG191/11 Question What are the possible outcomes for people who are critically ill and have COVID-19-associated...